We re #28! TSX rides commodity rally to outpace Dow Industrials
Colin Stewart s Top Picks: June 30, 2021
U.S. stock euphoria abates at end of big first half
Bruce Campbell s Top Picks: June 29, 2021
Lorne Steinberg s Top Picks: June 28, 2021
Wall Street and C-Suite grapple with a meme-stock new normal
Haters everywhere in stock market after S&P 500 s big first half
Larry Berman: Warning, the making of the Mother of all crashes
Ryan Bushell s Top Picks: June 25, 2021
Banks easily clear U.S. stress tests, setting stage for payouts
Pattie Lovett-Reid: Investors need to get realistic about return expectations
Stan Wong s Top Picks: June 24, 2021
BofA favours Canada stocks with big discount to frothy S&P 500
IndiaIndia s Cadila gets approval to repurpose Hepatitis C drug for COVID-19
Reuters
2 minutes read
India s Cadila Healthcare Ltd (CADI.NS) has received restricted emergency use approval from local regulators to use a Hepatitis C drug as a treatment for moderate COVID-19 in adults, the drugmaker said on Friday.
The approval follows promising results from a late-stage study of the drug, and comes in the middle of a massive wave of COVID-19 cases in India, which has overwhelmed its health system and left many hospitals short of critical oxygen supplies.
Cadila said patients given its therapy in clinical trials had shown lesser need for supplemental oxygen, which is given to seriously ill COVID-19 patients to increase its supply in the blood and lungs.
By Reuters Staff
2 Min Read
BENGALURU (Reuters) - India’s Cadila Healthcare Ltd has received restricted emergency use approval from local regulators to use a Hepatitis C drug as a treatment for moderate COVID-19 in adults, the drugmaker said on Friday.
The approval follows promising results from a late-stage study of the drug, and comes in the middle of a massive wave of COVID-19 cases in India, which has overwhelmed its health system and left many hospitals short of critical oxygen supplies.
Cadila said patients given its therapy in clinical trials had shown lesser need for supplemental oxygen, which is given to seriously ill COVID-19 patients to increase its supply in the blood and lungs.
April 5, 2021 | 5:41 pm Font Size
AAA
CADILA HEALTHCARE LTD. has sought approval from India’s regulators to use a Hepatitis C drug as a treatment for coronavirus disease 2019 (COVID-19). COURTESY OF CADILA HEALTHCARE LTD.
BENGALURU India’s Cadila Healthcare Ltd. has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 (coronavirus disease (2019) following promising interim results from a late-stage trial, the drug maker said on Monday.
A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges.
Cadila seeks nod to repurpose Hepatitis C drug for COVID-19 in India
This content was published on April 5, 2021 - 04:31
April 5, 2021 - 04:31
BENGALURU (Reuters) - India s Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges.
About 91% of patients treated with the drug tested negative for COVID-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said citing Phase-III clinical trial data.